Sugar Extract ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
97	Ulcerative colitis	1

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01496053 (ClinicalTrials.gov)	December 2011	15/12/2011	Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)	Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study	Ulcerative Colitis;Crohn's Disease;Inflammatory Bowel Disease	Dietary Supplement: AndoSan;Dietary Supplement: Sugar Extract	Oslo University Hospital	ImmunoPharma AS	Completed	18 Years	60 Years	All	100	Phase 2/Phase 3	Norway

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01496053 (ClinicalTrials.gov)	December 2011	15/12/2011	Anti-inflammatory Effect of Agaricus Blazei Murill in Inflammatory Bowel Disease (IBD)	Anti-inflammatory Effect of a Mushroom Extract (AndoSan)in Patients With Inflammatory Bowel Disease. A Prospective Study	Ulcerative Colitis;Crohn's Disease;Inflammatory Bowel Disease	Dietary Supplement: AndoSan;Dietary Supplement: Sugar Extract	Oslo University Hospital	ImmunoPharma AS	Completed	18 Years	60 Years	All	100	Phase 2/Phase 3	Norway